WS #16809
Novo Nordisk reported third-quarter results that significantly beat consensus, posting revenue of $11.9 billion and EPS of $4.02, driven largely by the successful launch of its oral GLP-1 formulation, Wegovy pills. The company raised its full-year adjusted EBIT guidance to a range of -2% to +2%, reversing prior expectations of a decline. This performance validates the durable demand for obesity treatments and provides a bright spot for the healthcare sector amidst broader macroeconomic volatility.
Novo Nordisk Earnings Beat
Novo Nordisk reported third-quarter results that significantly beat consensus, posting revenue of $11.9 billion and EPS of $4.02, driven largely by the successful launch of its oral GLP-1 formulation, Wegovy pills. The company raised its full-year adjusted EBIT guidance to a range of -2% to +2%, reversing prior expectations of a decline. This performance validates the durable demand for obesity treatments and provides a bright spot for the healthcare sector amidst broader macroeconomic volatility.